LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

LEO Pharma retains the option to co-commercialise oral programmes for dermatology outside the US and will exclusively hold global rights to topical STAT6 formulations in dermatology.

As part of the transaction, LEO Pharma has agreed to provide Timber with a bridge loan of up to $3.0 million, subject to certain conditions.

LEO Pharma presents late-breaking positive Phase 2a efficacy and safety results of LEO 138559 in moderate-to-severe atopic dermatitis ...

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

LEO Pharma announces the FDA approval of Adbry™ (tralokinumab-ldrm) for adults with moderate-to-severe atopic dermatitis.

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics ...

LEO Pharma is a leader in global dermatology with a mission that matches our own - a relentless pursuit to help patients suffering from skin diseases.